Skip to main content
. 2018 Mar 27;9(23):16489–16500. doi: 10.18632/oncotarget.24740

Figure 2. TpeL effects the oncogenic and paradoxical activation of MAPK signaling in SBCL2 cells.

Figure 2

(A) Western blot analysis of SBCL2 cells intoxicated with increasing concentrations of TpeL for 4 h. Rasnon-gluc., pMEK, pERK, tERK, and tubulin were probed. A representative blot of three independent experiments is shown. (B) Statistical analysis of phosphorylated MEK and ERK following TpeL treatment as presented in A. (C) Western blot analysis of SBCL2 cells intoxicated with increasing concentrations of TpeL for 4 h following preincubation with Vemurafenib for 2 h. Rasnon-gluc., pMEK, pERK, tERK, and tubulin were probed. A representative blot of three independent experiments is shown. (D) Statistical analysis of phosphorylated MEK and ERK following treatment with Vemurafenib and TpeL as presented in C.